^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | oleclumab (MEDI9447) (CD73 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Published date:
04/05/2023
Excerpt:
Patients received oleclumab 5–40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg intravenously Q2W....192 patients were enrolled into 4 monotherapy (n = 42) and 4 combination therapy (n = 24) escalation cohorts....In the EGFRm NSCLC expansion cohort, 4 patients (9.5%) had PRs, with a median DoR of 14.8 months (range, 5.6–24.0; 1 response ongoing) (Fig. 4c). An additional 9 patients (21.4%) had SD ≥ 8 weeks. Overall, DC was ≥ 24 weeks in 6 (14.3%) patients.
DOI:
10.1007/s00262-023-03430-6
Trial ID:
